Inhalation Anesthesia Industry Overview
The global inhalation anesthesia market size was valued at USD 1.1 billion in 2021 and is projected to expand at a CAGR of 9.0% in the forecast period. The market growth can be attributed to the growing number of surgical procedures. Inhalation anesthesia facilitates higher patient outcomes as compared to intravenous anesthesia. Administration of an anesthetic agent through the respiratory tract allows controllable and effective sedation, which is cost-effective and safe. Various advantages of inhalation anesthesia over intravenous anesthesia are primarily driving the market growth. Inhalation anesthesia is considered to be the best alternative for patients who are on ventilation for more than 24 hours as it becomes easy to monitor the patient’s health. Hence, higher patient benefits associated with the use of inhalation anesthesia as compared to intravenous anesthesia is expected to drive revenue growth in the forecast period.
According to NCBI data, around 310 million major surgeries are performed across the world every year, out of which approximately 40-50 million are performed in the U.S. and 20 million in Europe. During the post-COVID-19 situation, there has been an increase in the number of elective surgeries, which has further boosted the demand for inhalation anesthetics. In 2020, during the COVID-19 pandemic, the Centers for Medicare and Medicaid Services recommended that hospitals minimize, postpone, or cancel elective surgeries which have led to a reduction in the number of surgeries by 48% in the U.S. Inhaled anesthetics are commonly used to provide general anesthesia. Based on NIH data, nearly 60,000 people undergo a surgical procedure under general anesthesia. Life-saving surgical procedures such as brain surgery, open-heart surgery, or organ transplantation would not have been possible without general anesthesia, thereby, boosting the demand for inhaled anesthetic drugs.
Gather more insights about the market drivers, restraints, and growth of the Global Inhalation Anesthesia market
Inhaled anesthetics help in reducing patients’ overall healthcare expenditure. Patients who have undergone surgery and are critically ill are usually admitted to ICUs, which increases their healthcare expenditure due to an increase in the duration of hospital stays. Inhalation anesthesia helps surgeons design the dosage to avoid the additional hospital stay. However, this is not possible in the case of intravenous anesthesia which helps reduce the patient’s overall healthcare expenditure.
Increase in greenhouse gas emissions is one of the major reasons for global warming and climate change. Inhaled anesthetic gases including sevoflurane, isoflurane, and desflurane are potent greenhouse gases, which have more deteriorating effects compared to normal carbon dioxide emissions. Globally, these anesthetic gases contribute up to 1% of the global carbon dioxide emissions as they have a longer shelf life and cause greater environmental damage.
Browse through Grand View Research's Pharmaceuticals Industry Research Reports.
Inhalation and Nasal Spray Generic Drugs Market - The global inhalation and nasal spray generic drugs market size was valued at USD 17.50 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 8.96% from 2022 to 2030.
Opioids Market - The global opioids market size was valued at USD 22.66 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 1.2% from 2022 to 2030.
Inhalation Anesthesia Market Segmentation
Grand View Research, has segmented the inhalation anesthesia market report based on drug, application, and region.
Inhalation Anesthesia Drug Outlook (Revenue, USD Million, 2016 - 2030)
- Sevoflurane
- Desflurane
- Isoflurane
- Halothane
Inhalation Anesthesia Application Outlook (Revenue, USD Million, 2016 - 2030)
- Induction
- Maintenance
Inhalation Anesthesia End-Use Outlook (Revenue, USD Million, 2016 - 2030)
- Hospitals
- Ambulatory Surgical Centers
- Others
Inhalation Anesthesia Regional Outlook (Revenue, USD Million, 2016 - 2030)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa (MEA)
Market Share Insights
January 2019: Sandoz International GmbH launched Desflurane liquid as an inhalation agent for induction and maintenance of anesthesia, required for inpatient and outpatient surgery in adults & pediatric patients in the U.S. It was the first generic of Suprane in the U.S.
Key Companies profiled:
Some of the prominent players in the global inhalation anesthesia market include:
- Halocarbon Products Corporation
- Baxter
- AbbVie
- Lunan Pharmaceutical Group
- Piramal Enterprises Ltd.
- Sandoz International GmbH (Novartis)
- Fresenius Kabi Ag
Order a free sample PDF of the Inhalation Anesthesia Market Intelligence Study, published by Grand View Research.
No comments:
Post a Comment